[1]
|
世界卫生组织. 心血管疾病[EB/OL].
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds), 2021-06-11.
|
[2]
|
国家卫生健康委员会. 中国卫生健康统计年鉴2019版[M]. 北京: 中国协和医科大学出版社, 2019: 284.
|
[3]
|
胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220.
|
[4]
|
Ben-Gal, Y., Mohr, R., Feit, F., et al. (2015) Surgical versus Percutaneous Coronary Revascularizationfor Multivessel Diseasein Diabetic Pa-tients with Non-ST-Segment-Elevation Acute Coronary Syndrome. Circulation Cardiovascular Interventions, 8, 16-21. https://doi.org/10.1161/CIRCINTERVENTIONS.114.002032
|
[5]
|
徐爱萍. 冠心病多支血管病变完全血运重建的临床疗效分析[J]. 中国医药指南, 2015(30): 58-59.
|
[6]
|
Bundhun, P.K., Wu, Z.J. and Chen, M.H. (2016) Coro-nary Artery Bypass Surgery Compared with Percutaneous Coronary Interventions in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 6 Randomized Controlled Trials. Cardiovascular Dia-betology, 15, Article No. 2.
https://doi.org/10.1186/s12933-015-0323-z
|
[7]
|
Ross, R. (1993) The Pathogenesis of Atherosclerosis: Aperspec-tive for the 1990s. Nature, 362, 801-809.
https://doi.org/10.1038/362801a0
|
[8]
|
Kereiakes, D.J. (2014) Reassessing the Importance of Complete versus In-complete Coronary Revascu Larization. Reviews in Cardiovascular Medicine, 15, 24-30. https://doi.org/10.3909/ricm0714
|
[9]
|
Tsiantoulas, D., Diehl, C.J., Witztum, J.L. and Binder, C.J. (2014) B Cells and Humoral Immunity in Atherosclerosis. Circulation Research, 114, 1743-1756. https://doi.org/10.1161/CIRCRESAHA.113.301145
|
[10]
|
Leviner, D.B., Torregrossa, G. and Puskas, J.D. (2018) Incomplete Revascularization: What the Surgeon Needs to Know. Annals of Cardiothoracic Surgery, 7, 463-469. https://doi.org/10.21037/acs.2018.06.07
|
[11]
|
Ridker, P.M., Everett, B.M., Thuren, T., et al. (2017) Antiinflamma-tory Therapy Withcanakinumab for Atheroscl Erotic Disease. The New England Journal of Medicine, 377, 1119-1131. https://doi.org/10.1056/NEJMoa1707914
|
[12]
|
Bauters, C. and Isner, J.M. (1997) Thebiology of Restenosis. Pro-gress in Cardiovascular Diseases, 40, 107-116.
https://doi.org/10.1016/S0033-0620(97)80003-5
|
[13]
|
Montone, R.A., Meucci, M.C. and Niccoli, G. (2020) The Management of Non-Culprit Coronary Lesions in Patients with Acute Coronary Syndrome. European Heart Journal Supplements, 22, L170-L175.
https://doi.org/10.1093/eurheartj/suaa175
|
[14]
|
Ibanez, B., James, S., Agewall, S., et al. (2018) 2017 ESC Guide-lines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the Eu-ropean Society of Cardiology (ESC). European Heart Journal, 39, 119-177. https://doi.org/10.1093/eurheartj/ehx393
|
[15]
|
Smits, P.C., Abdel-Wahab, M., Neumann, F.J., et al. (2017) Frac-tional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. The New England Journal of Medicine, 376, 1234-1244.
https://doi.org/10.1056/NEJMoa1701067
|
[16]
|
Mehta, S.R., Wood, D.A., Storey, R.F., et al. (2019) Complete Re-vascularization with Multivessel PCI for Myocardial Infarction. The New England Journal of Medicine, 381, 1411-1421. https://doi.org/10.1056/NEJMoa1907775
|
[17]
|
Pasceri, V., Patti, G., Pelliccia, F., et al. (2018) Complete Revascu-larization during Primary Percutaneous Coronary Intervention Reduces Death and Myo-Cardial Infarction in Patients with Multivessel Disease Meta-Analysis and Meta-Regression of Randomized Trials. JACC: Cardiovascular Interventions, 11, 833-843.
https://doi.org/10.1016/j.jcin.2018.02.028
|
[18]
|
Hu, P.T., Jones, W.S., Glorioso, T.J., et al. (2018) Predictors and Outcomes of Staged versus One-Time Multivessel Revascularization in Multivessel Coronary Artery Disease Insights from the VA CART Program. JACC: Cardiovascular Interventions, 11, 2265-2273. https://doi.org/10.1016/j.jcin.2018.07.055
|
[19]
|
Gershlick, A.H., Khan, J.N., Kelly, D.J., et a1. (2015) Randomized Trial of Complete versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Inter-vention for STEMI and Multivessel Disease. Journal of the American College of Cardiology, 65, 963-972. https://doi.org/10.1016/j.jacc.2014.12.038
|
[20]
|
Glaser, R., Selzer, F., Faxon, D.P., Laskey, W.K., Cohen, H.A., Slater, J., Detre, K.M. and Wilensky, R.L. (2005) Clicinal Progression of Incidental, Asympto Maticles Ionsdi Scovered during Culpritvessel Coronary Intervention. Circulation, 111, 143-149. https://doi.org/10.1161/01.CIR.0000150335.01285.12
|
[21]
|
Yang, Y.L., Wu, C.H., Hsu, P.F., et al. (2020) Sys-temic Immune-Inflammation Index (SII) Predicted Clinical Outcome in Patients with Coronary Artery Disease. European Journal of Clinical Investigation, 50, e13230.
https://doi.org/10.1111/eci.13230
|
[22]
|
Candemir, M., Kiziltunç, E., Nurkoç, S., et al. (2021) Relationship between Systemic Immune-Inflammation Index (SII) and the Severity of Stable Coronary Artery Disease. Angiology, 72, 575-581.
https://doi.org/10.1177/0003319720987743
|
[23]
|
Nakachi, T., Kosuge, M., Hihi, K., Ebina, T., Hashiba, K., Mit-suhashi, T., Endo, M., Umemura, S. and Kimura, K. (2008) Creactive Proteine Levation and Rapidang Iographi Cpro-gressiono Fnoncul Pritlesion Inpatien Tswithnon-ST-Segmente Levationa Cutecoronary Syndrome. Circulation Journal, 72, 1953-1959. https://doi.org/10.1253/circj.CJ-08-0185
|
[24]
|
Lemesle, G., DeLabriolle, A., Bonello, L., Torguson, R., Kaneshige, K., Xue, Z., Suddath, W.O., Satler, L.F., Kent, K.M., Lindsay, J., Pichard, A.D. and Waksman, R. (2009) Incidence, Predictors, and Outcome of New, Subsequent Lesions Treated with Percutaneou Scoronary Intervention in Pa-tients Presenting with Myocardial Infarction. The American Journal of Cardiology, 103, 1189-1195. https://doi.org/10.1016/j.amjcard.2009.01.029
|
[25]
|
Xu, Y.L., Li, J.J., Xu, B., Zhu, C.G., Yang, Y.J., Chen, J.L., Qiao, S.B., Yuan, J.Q., Qin, X.W., Ma, W.H., Yao, M., Liu, H.B., Wu, Y.J., Chen, J., You, S.J., Dai, J., Xia, R. and Gao, R.L. (2011) Increased Plasma C-Reactive Protein Level Predicts Rapid Progression of Non-Target Atherosclerotic Lesions in Patients with Stable Angina after Stenting. Chinese Medical Journal, 124, 3022-3029.
|
[26]
|
Zheng, J.L., Lu, L., Hu, J., et al. (2010) Increased Serum YKL-40 and C-Reactive Protein Levelsa Reasso Ciated with Angiographicles Ionprogressionin Patients with Coronaryartery Disease. Atherosclerosis, 210, 590-595.
https://doi.org/10.1016/j.atherosclerosis.2009.12.016
|
[27]
|
Braunwald, E., Antman, E.M., Beasley, J.W., et al. (2000) ACC/AHA Guidelines for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Journal of the American College of Cardiology, 36, 970-1062.
https://doi.org/10.1016/S0735-1097(00)00889-5
|
[28]
|
Murthy, P., Zenati, M.S., Al Abbas, A.I., et a1. (2020) Prognostic Value of the Systemic Immune. Inflammation Index (SII) after Neoadjuvant Therapy for Patients with Re-sected Pancreatic Cancer. Annals of Surgical Oncology, 27, 898-906.
https://doi.org/10.1245/s10434-019-08094-0
|
[29]
|
De Waha, S., Patel, M.R., Granger, C.B., et al. (2017) Relation-ship between Microvascular Obstruction and Adverse Events Following Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: An Individual Patient Data Pooled Analysis from Seven Randomized Trials. European Heart Journal, 38, 3502-3510.
https://doi.org/10.1093/eurheartj/ehx414
|
[30]
|
李金萍, 巨名飞, 陈立. 炎症因子与急性冠脉综合征关系的研究现状[J]. 河北医学, 2015(6): 1008-1010.
|
[31]
|
Ndrepepa, G., Neumarm, F.J., Schulz, S., Fusaro, M., Cassese, S., Byrne, R.A. and Richardt, G. (2014) Incidence and Prognostic Value of Bleeding after Percutaneous Coronary Interven-tion in Patients Older than 18 Years of Age. Catheterization and Cardiovascular Interventions, 83, 182-189. https://doi.org/10.1002/ccd.25189
|
[32]
|
Niccoli, G., Montone, R.A., Ferrance, G. and Crea, F. (2010) The Evolving Role of Inflamma-Tory Biomakers in Risk Assessment after Stent Implantation. Journal of the American College of Car-diology, 56, 1783-1793.
https://doi.org/10.1016/j.jacc.2010.06.045
|
[33]
|
高大顺. 血小板指标与冠心病患者PCI术后非罪犯血管病变进展的关系[D]: [硕士学位论文]. 郑州: 郑州大学, 2019.
|
[34]
|
陈文明, 李东宝, 陈晖, 等. 冠状动脉病变支架后非罪犯病变快速进展的预测因子[J]. 首都医科大学学报, 2013, 34(1): 90-94. https://doi.org/10.3969/j.issn.1006-7795.2013.01.017
|
[35]
|
Morice, M.C., Serruys, P.W. and Sousa, J.E. (2002) A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. The New England Journal of Medicine, 346, 1773-1780.
https://doi.org/10.1056/NEJMoa012843
|
[36]
|
Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., Shaughnessy, C.O., Caputo, R.P., Kereiakes, D.J., Williams, D.O., Teirstein, P.S. and Jaeger, J.L. (2003) Siroli-mus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. The New England Journal of Medicine, 349, 1315-1323.
https://doi.org/10.1056/NEJMoa035071
|
[37]
|
Stone, G.W., Ellis, S.G., Cox, D.A., Hermiller, J., Shaughnessy, C.O. and Mann, J.T. (2004) A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. The New England Journal of Medicine, 350, 221-231.
https://doi.org/10.1056/NEJMoa032441
|
[38]
|
王章龙, 刘瑞麟, 张波, 等. 非罪犯血管病变的评估及其在血运重建中的作用及研究进展[J]. 心血管病学进展, 2023, 44(9): 845-848, 852. https://doi.org/10.16806/J.Cnki.Issn.1004-3934.2023.09.018
|
[39]
|
Diletti, R., Den Dekker, W.K., Bennett, J., Schotborgh, C.E., Van Der Schaaf, R., Sabaté, M., Moreno, R., Ameloot, K., Van Bommel, R., Forlani, D., Van Reet, B., Esposito, G., Dirksen, M.T., Ruifrok, W.P.T., Everaert, B.R.C., Van Mieghem, C., Elscot, J.J., Cummins, P., Lenzen, M., Brugaletta, S., Boersma, E., Van Mieghem, N.M. and BIOVASC Investigators (2023) Immediate versus Staged Complete Revascularisation in Patients Presenting with Acute Coronary Syndrome and Multivessel Coronary Disease (BIOVASC): A Prospective, Open-Label, Non-Inferiority, Randomised Trial. The Lancet, 401, 1172-1182. https://doi.org/10.1016/S0140-6736(23)00351-3
|